However, the nod is subject to the condition that the Interferon-Gamma Release Assay (IGRA) test for latent TB should be a part of the screening of subjects in the study.
This came after the drug maker Lupin presented the protocol to conduct Phase I study titled "A Double Blind, Balanced, Randomized, Single-Dose, Single-Period, Two-Treatment, Parallel Comparative Pharmacokinetics Study of Lupin’s Certolizumab pegol with US Licensed Cimzia (certolizumab pegol) in Healthy, Adult, Human Subjects" for export purpose vide Protocol No. LBC-P-015-25. Version: 00 Date: 21 Apr 2025.
Certolizumab pegol is a tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
Certolizumab targets the activation of TNF-alpha with high affinity (KD 90 pM and IC90 0.004 mcg/ml), which inhibits the downstream inflammatory process. It acts by binding and neutralizing the soluble and membrane portions of TNF-alpha without inducing complement or antibody-dependent cytotoxicity due to the lack of the Fc region. The inhibition of TNF-alpha is achieved in a dose-dependent manner and it does not present activity against lymphotoxin alpha (TNF-beta).
Certolizumab pegol (Cimzia) is used to treat several inflammatory autoimmune diseases by neutralizing tumor necrosis factor-alpha (TNF-α), a chemical that causes inflammation. Its indications include Crohn's disease (CD), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).
At the recent SEC meeting for Gastroenterology and Hepatology, the expert panel reviewed the phase I protocol to conduct a Phase I study titled "A Double-Blind, Balanced, Randomized, Single-Dose, Single-Period, Two-Treatment, Parallel, Comparative Pharmacokinetics Study of Lupin’s Certolizumab Pegol with US Licensed Cimzia (certolizumab pegol) in Healthy, Adult, Human Subjects" for export purposes vide Protocol No. LBC-P-015-25. Version: 00 Date: 21 Apr 2025.
After detailed deliberation, the committee recommended the firm to conduct the clinical trial with the condition that IGRA test for latent TB should be a part of the screening of subjects in the study.
Accordingly, the expert panel suggested that the firm should submit a revised protocol to CDSCO for further evaluation.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.